Abstract:Background: Cancer cells undergo global reprogramming of cellular metabolism to satisfy demands of energy and biomass during proliferation and metastasis. Computational modeling of genome-scale metabolic models is an effective approach for designing new therapeutics targeting dysregulated cancer metabolism by identifying metabolic enzymes crucial for satisfying metabolic goals of cancer cells, but nearly all previous studies neglect the existence of metabolic demands other than biomass synthesis and trade-offs between these contradicting metabolic demands. It is thus necessary to develop computational models covering multiple metabolic objectives to study cancer metabolism and identify novel metabolic targets. Methods: We developed a multi-objective optimization model for cancer cell metabolism at genome-scale and an integrated, data-driven workflow for analyzing the Pareto optimality of this model in achieving multiple metabolic goals and identifying metabolic enzymes crucial for maintaining cancer-associated metabolic phenotypes. Using this workflow, we constructed cell line-specific models for a panel of cancer cell lines and identified lists of metabolic targets promoting or suppressing cancer cell proliferation or the Warburg Effect. The targets were then validated using knockdown and over-expression experiments in cultured cancer cell lines. Results: We found that the multi-objective optimization model correctly predicted phenotypes including cell growth rates, essentiality of metabolic genes and cell line specific sensitivities to metabolic perturbations. To our surprise, metabolic enzymes promoting proliferation substantially overlapped with those suppressing the Warburg Effect, suggesting that simply targeting the overlapping enzymes may lead to complicated outcomes. We also identified lists of metabolic enzymes important for maintaining rapid proliferation or high Warburg Effect while having little effect on the other. The importance of these enzymes in cancer metabolism predicted by the model was validated by their association with cancer patient survival and knockdown and overexpression experiments in a variety of cancer cell lines. Conclusions: These results confirm this multi-objective optimization model as a novel and effective approach for studying trade-off between metabolic demands of cancer cells and identifying cancer-associated metabolic vulnerabilities, and suggest novel metabolic targets for cancer treatment.

Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways

Computational modeling of cancer cell metabolism along the catabolic-anabolic axes

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

Towards decoding the coupled decision-making of metabolism and epithelial-mesenchymal transition in cancer

MMP3C: an in-silico framework to depict cancer metabolic plasticity using gene expression profiles

Uncovering the Underlying Mechanisms of Cancer Metabolism Through the Landscapes and Probability Flux Quantifications

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Dysregulated metabolism contributes to oncogenesis

The cancer metabolic reprogramming and immune response

Computational dissection of the regulatory mechanisms of aberrant metabolism in remodeling the microenvironment of breast cancer

Cancer Metabolism and Intervention Therapy

A Single-Cell Network Approach to Decode Metabolic Regulation in Gynecologic and Breast Cancers

Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets

Metabolic Reprogramming for Cancer Cells and Their Microenvironment: Beyond the Warburg Effect

Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation

Metabolic rewiring and communication in cancer immunity

Regulatory Role of Cancer Microenvironment in Cancer Metabolism

Mechanisms governing lineage plasticity and metabolic reprogramming in cancer

Insights into Metabolic Reprogramming in Tumor Evolution and Therapy

Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs

Identification of Cancer–associated Metabolic Vulnerabilities by Modeling Multi-Objective Optimality in Metabolism